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ABSTRACT
Reduced HDL (high-density lipoprotein) concentration in the MetS (metabolic syndrome) is
associated with increased risk of cardiovascular disease and is related to defects in HDL-apoA-II
(apolipoprotein A-II) kinetics. Dietary restriction is the most commonly used weight loss strategy.
Inthepresentstudy,weexaminedtheeffectofweightlossonHDL-apoA-IIkineticsinmenwiththe
MetS at the start and end of a 16-week intervention trial of a hypocaloric low-fat diet (n=20) com-
paredwithaweightmaintenancediet(n=15),usingastableisotopetechniqueandcompartmental
modelling. The low-fat diet achieved a signiﬁcant reduction (P<0.01) in BMI (body mass index),
abdominal fat compartments and HOMA (homoeostasis model assessment) score compared with
weight maintenance. Weight loss also signiﬁcantly (P<0.05) decreased both the production rate
(−23%)andFCR(fractionalcatabolicrate)(−12%)ofHDL-apoA-II,accountingforanetdecrease
inapoA-IIconcentration(−9%).ReductionsintheHDL-apoA-IIproductionrateweresigniﬁcantly
associated with changes in body weight (r=0.683, P<0.01), plasma triacylglycerols (triglycerides)
(r=0.607, P<0.01) and, to a lesser extent, plasma insulin (r=0.440, P=0.059) and HOMA-IR
(HOMA of insulin resistance) (r=0.425, P=0.069). Changes in the apoA-II FCR were also signiﬁc-
antlyassociatedwithreductionsinvisceraladiposetissuemass(r=0.561,P=0.010).Inconclusion,
in obese men with the MetS, short-term weight loss with a low-fat low-caloric diet lowers plasma
apoA-II concentrations by decreasing both the production and catabolism of HDL-apoA-II. The
cardiometabolic signiﬁcance of this effect on HDL metabolism remains to be investigated further.
INTRODUCTION
The MetS (metabolic syndrome) portends diabetes and
CVD (cardiovascular disease) [1]. Dyslipoproteinaemia,
reﬂected by elevated plasma triacylglycerol (triglyceride)
and reduced HDL (high-density lipoprotein) concen-
trations, is a cardinal feature of the MetS that indepen-
dently predicts CVD [2] and is accordingly a therapeutic
target for risk reduction [3].
Apo (apolipoprotein) A-I and apoA-II are the major
apolipoproteins of HDL, which are extremely diverse in
structureandfunction[4].Compellingevidencesupports
the anti-atherogenic role of apoA-I in preventing CVD
[5]. By contrast, the function of apoA-II is less consistent
[6]. Animal studies have suggested that apoA-II may
promoteatherosclerosis[7,8].Some,butnotall,epidemi-
ological studies have demonstrated a positive association
withCVDinhumans[9–13].Ininsulinresistance,hepatic
overproduction of VLDL (very-low-density lipopro-
tein), together with decreased LPL (lipoprotein lipase)
activity,resultsinexpansionintheVLDL-triacylglycerol
pool and enhances CETP (cholesteryl ester transfer
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protein)-mediated hetero-exchange of neutral lipids
amonglipoproteins,leadingtoincreasedHDLtriacylgly-
cerolconcentrations.SubsequenthydrolysisbyHL(hep-
atic lipase), which is overactive in insulin resistance and
obesity, results in a thermodynamically unstable HDL
particlethatiscatabolizedrapidlybytheliverandkidney
[14,15]. Using stable isotopes and multi-compartmental
modelling, we have shown previously an increased
catabolism of HDL-apoA-I and -apoA-II particles in
male subjects with MetS and IR (insulin resistance) [16].
Weight reduction by dietary restriction is asso-
ciated with improvements in a number of CVD
factors, including dyslipidaemia and IR [17]. We have
demonstrated previously that in obese men weight
reduction between 5 to 10 kg with a low-fat low-
caloric diet effectively decreases hepatic VLDL-apoB
secretion and increased LDL (low-density lipoprotein)-
apoB catabolism [18]. Our previous ﬁndings also suggest
that weight loss inﬂuences the kinetics of HDL by
decreasing both catabolism and production of apoA-I
without signiﬁcantly altering HDL-apoA-I and HDL-
cholesterol concentrations [19]. However, there are no
kinetic data on the effect of weight loss on apoA-II
metabolism in these subjects.
We therefore extend our previous study by investi-
gating the effect of short-term weight loss on HDL-
apoA-II kinetics in subjects with the MetS. Given
that both apoA-I and apoA-II share similar metabolic
pathways, we hypothesized that weight loss would
decrease the FCR (fractional catabolic rate) and produc-
tion rate of HDL-apoA-II.
MATERIALS AND METHODS
Subjects and study design
The details of subject selection and study design have
been described previously [19]. Brieﬂy, 35 men with the
MetS were randomized to either a hypocaloric low-fat
diet for 14 weeks, immediately followed by a 2-week
weight stabilization period, or to weight maintenance on
an isocaloric diet for 16 weeks. HDL-apoA-II kinetics
were measured after a 14 h fast using primed (1 mg/kg
of body weight) and constant (1 mg·kg−1 of body
weight·h−1) intravenous infusion of 1-[13C]leucine
(99.5% enrichment; Tracer Technologies) for 10 h [19].
Bodycompositionwasestimated,asdescribedpreviously
[19], using a Holtain body composition analyser from
which total fat mass and FFM (fat-free mass) were
derived. Abdominal visceral ATM (adipose tissue
mass) and subcutaneous ATM were estimated following
magneticresonanceimaging[20].Subjectswererequested
to maintain their usual level of physical activity and
alcohol intake. Dietary intakes were assessed by 7-day
recall questionnaires and alcohol diaries during weight
loss and weight maintenance. Three day dietary diaries
were completed every 3 weeks by both groups, and
these were analysed using DIET 4 nutrient calculation
software (Xyris Software). All procedures were repeated
after the 16-week intervention. The study was approved
by the Royal Perth Hospital Ethics Committee, and all
participants provided written informed consent.
Isolation and measurement of isotopic
enrichment of HDL-apoA-II
HDL-apoA-II were isolated from plasma by sequential
ultracentrifugation,separatedbySDS/PAGEandblotted
on to a PVDF membrane; apoA-II bands were excised
from the PVDF membrane, hydrolysed overnight
(6 mol/l HCl, 110◦C) and dried for derivatization [16].
Isotopic enrichment of apoA-II was determined using
negative chemical ionization by GC/MS.
Biochemical measurements
Fasting plasma lipid and lipoprotein concentrations were
determined by standard methods. Plasma glucose and
NEFAs (non-esteriﬁed fatty acids) were measured by
enzymatic colorimetric methods, and insulin was de-
termined by immunoenzymometry. These methods have
been described elsewhere [19]. HOMA-IR (homoeo-
stasis model assessment of IR) score was used as an
estimate of IR [21]. Plasma lathosterol concentration
(a surrogate marker of cholesterol synthesis) was
measured by GC/MS [22].
Model of apoA-II metabolism
Tracer-to-tracee ratios were modelled using SAAM-II
(University of Washington, Seattle, WA, U.S.A.) from
which FCRs of HDL-apoA-II were estimated from the
best ﬁt of the model to the data. The apoA-II
compartmental model consisted of three compartments
(Figure 1). Compartment 1 represents the tracer input
(plasma leucine enrichment), which is incorporated
into an intrahepatic compartment (compartment 2) that
accounts for the synthesis and secretion of apoA-II
into the HDL fraction (compartment 3). HDL-apoA-
II transport rate was calculated by multiplying the FCR
by pool size (mg·kg−1 of FFM·day−1).
Statistical analyses
All analyses were carried out using SPSS. Skewed data
were log-transformed where appropriate. Treatment
effects of the weight loss group relative to the weight
maintenance group were analysed using general linear
modelling with adjustments for baseline covariates.
Associations between absolute changes in variables in the
weight loss group were examined using simple regression
model. Group differences at baseline were analysed using
independent Student t tests. Statistical signiﬁcance was
deﬁned as P<0.05.
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Figure 1 Compartmental model describing HDL-apoA-II
tracer kinetics
Compartment 1 represents the tracer input which is incorporated into an
intrahepatic compartment (compartment 2) that accounts for the synthesis and
secretion of apoA-II into the HDL fraction (compartment 3).
RESULTS
Table 1 shows the clinical and biochemical characteristics
of the subjects studied. On average, they were middle-
aged, centrally obese, normotensive, insulin-resistant
and dyslipidaemic (elevated plasma triacylglycerols and
total apoB, and low HDL-cholesterol). There were no
signiﬁcant group differences in any of the variables at
baseline. Average daily energy and nutrient intake of the
35 obese subjects studied was: 10045+ −2406 kJ, 36+ −6%
energy from fat, 38+ −8% energy from carbohydrates,
20+ −3% energy from protein and 6+ −6% energy from
alcohol (values are means+ −S.D.). Nutrient intake did
not differ between patients randomized to weight loss or
weight maintenance.
Compared with the weight maintenance group, the
weight loss group achieved signiﬁcant reductions in
body weight (−12%, P<0.001), BMI (body mass
index; −13%, P<0.001), waist circumference (−9%,
P<0.001), mean arterial pressure (−9%,P<0.01), total
fat mass (−30%, P<0.001), visceral ATM (−24%,
P<0.001) and subcutaneous ATM (−23%, P<0.001)
following the weight loss intervention. Compared with
the weight maintenance group, weight loss also resulted
in signiﬁcant decreases (P<0.05) in plasma cholesterol
(−12%), triacylglycerols (−43%), non-HDL-cho-
lesterol (−14%), LDL-cholesterol (−8%), total apoB
(−16%), apoA-II (−9%) and lathosterol (−23%), as
well as insulin (−41%) and HOMA-IR score (−46%).
Therewerenosigniﬁcanteffectsofweightlossonplasma
concentrations of HDL-cholesterol, apoA-I and glucose
when compared with the weight maintenance group.
Compared with the weight maintenance group,
subjects in the weight loss group signiﬁcantly (P<0.001
Table 1 Anthropometric characteristics, plasma lipids and lipoproteins and measures of insulin resistance before and after
weight loss and during weight maintenance
Values are means+ −S.E.M. Effect of weight loss was tested using general linear modelling after adjusting for the weight maintenance group; ‡P <0.05, †P <0.01
and ∗P <0.001.
Weight loss group (n=20) Weight maintenance group (n=15)
Characteristic Week 0 Week 16 Week 0 Week 16
Weight (kg) 109+ −29 6 + −3∗ 105+ −3 109+ −2
BMI (kg/m2)3 5 + −1.0 31+ −0.7∗ 33+ −0.7 35+ −0.9
Waist circumference (cm) 112+ −2 103+ −2∗ 113+ −2 113+ −2
Mean blood pressure (mmHg) 95.4+ −2.8 86.4+ −2.8† 96.6+ −3.0 94.7+ −3.1
Total fat mass (kg) 42.6+ −2.7 30.0+ −1.9∗ 38.8+ −1.8 44.1+ −2.8
FFM (kg) 65.4+ −1.9 62.5+ −2.0 63.9+ −1.7 64.0+ −1.8
Visceral ATM (kg) 7.1+ −0.5 5.4+ −0.4∗ 6.9+ −0.4 6.7+ −0.4
Total subcutaneous ATM (kg) 8.4+ −0.7 6.5+ −0.4∗ 9.6+ −0.7 9.9+ −0.7
Cholesterol (mmol/l) 6.0+ −0.3 5.2+ −0.2† 6.0+ −0.2 6.0+ −0.2
Triacylglycerol (mmol/l) 3.5+ −0.6 2.0+ −0.2∗ 2.9+ −0.6 2.7+ −0.4
HDL-cholesterol (mmol/l) 1.0+ −0.04 1.1+ −0.05 1.0+ −0.04 1.0+ −0.04
LDL-cholesterol (mmol/l) 3.3+ −0.2 3.0+ −0.2‡ 3.9+ −0.2 3.9+ −0.29
Non-HDL-cholesterol (mmol/l) 4.9+ −0.3 4.2+ −0.2† 4.8+ −0.2 4.9+ −0.2
ApoB-100 (g/l) 1.2+ −0.06 1.0+ −0.06† 1.2+ −0.06 1.2+ −0.05
ApoA-I (g/l) 1.3+ −0.05 1.3+ −0.04 1.2+ −0.04 1.2+ −0.02
ApoA-II (g/l) 0.33+ −0.01 0.30+ −0.01‡ 0.31+ −0.01 0.32+ −0.02
Lathosterol (μmol/l) 17.4+ −3.4 11.9+ −2.4‡ 14.5+ −2.1 14.4+ −2.0
Glucose (mmol/l) 5.7+ −0.2 5.3+ −0.1 5.4+ −0.2 5.5+ −0.3
Insulin (milli-units/l) 14+ −28 + −1∗ 18+ −31 6 + −2
HOMA-IR score 3.7+ −0.5 2.0+ −0.2† 4.6+ −0.8 4.0+ −0.6
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Figure 2 HDL-apoA-II FCR and production rate before and after weight loss and weight maintenance
for both) reduced their total energy (−37%;
mean+ −S.E.M., 9782+ −438 compared with 6143+ −
363 KJ) and fat intake (−30%; 37+ −1 compared with
26+ −2%),andincreasedtheircarbohydrateconsumption
(+30%; 37+ −2 compared with 48+ −2%), all changes be-
ing statistically signiﬁcant (P<0.001), during the weight
loss period. Alcohol intake in the weight loss group was
notsigniﬁcantlydifferentbeforeorafterweightloss.Nu-
trient intake did not change in the subjects in the weight
maintenance group during the 16-week intervention. In
the weight loss group, there were no signiﬁcant correl-
ations between changes in dietary intake and changes in
apoA-II kinetics during weight loss or at weight main-
tenance.Intheweightlossgroup,therewasnosigniﬁcant
associations between changes in apoA-II kinetics and
changes in nutrient intake during weight maintenance at
end of study. There was also no change in reported phys-
ical activity levels during the study in either the weight
loss or weight maintenance groups (results not shown).
Figure 2 shows the kinetic indices for HDL-apoA-II
metabolism after weight loss compared with the weight
maintenance group. There were no signiﬁcant group
differences in lipoprotein kinetics at baseline. Compared
with weight maintenance, weight loss signiﬁcantly
decreased the FCR (−12%) and production rate
(−23%) of HDL-apoA-II, accounting for a net decrease
in apoA-II concentration (−9%;seeT able1).
In univariate analyses, the change in plasma apoA-II
concentration with weight loss was signiﬁcantly
associated with corresponding changes in HDL-apoA-II
production rate (r=0.563, P<0.02), but not with
changes in FCR (r=−0.246, P>0.05). There was also
a signiﬁcant correlation (r=0.574, P<0.01) between
the reduction in HDL-apoA-II production rate and the
decrease in HDL-apoA-II FCR. Using HDL-apoA-I
kineticdatafromthesamesubjects[19],therewerenosig-
niﬁcant associations between changes in FCRs in HDL-
apoA-I and -apoA-II in the weight loss group (r=0.356,
P=0.135) nor between the changes in their production
(r=0.184,P=0.438);changesinapoA-IIkineticsdidnot
correlate with HDL-cholesterol and apoA-I levels.
Reductions in plasma apoA-II concentration and
HDL-apoA-II production rate were also associated
with changes in body weight (r=0.463, P<0.05
and r=0.683, P<0.01 respectively), BMI (r=0.509,
P<0.05 and r=0.672, P<0.01 respectively) and plasma
triacylglycerols (r=0.494, P<0.05 and r=0.607,
P<0.01 respectively). The association between changes
intheapoA-IIconcentration(partialr=0.484,P=0.042)
andapoA-IIproductionrate(partialr=0.643,P=0.004)
with weight reduction was independent of dietary fat
and carbohydrate intake at weight maintenance. In the
weight loss group, there was a trend to a signiﬁcance
in the association between the reduction in HDL-
apoA-II production rate and the decreases in plasma
insulin (r=0.440, P=0.059) and HOMA-IR (r=0.425,
P=0.069). Changes in apoA-II FCR were signiﬁcantly
associated with reductions in visceral ATM (r=0.561,
P=0.010).NeitherchangesinapoA-IIconcentrationnor
HDL-apoA-II FCR were associated with corresponding
changes in plasma insulin or HOMA-IR.
DISCUSSION
In the present study, we provide new results on the
effect of weight loss with a moderately low-fat diet on
HDL-apoA-II metabolism. We demonstrate that weight
loss principally decreased the production rate of HDL-
apoA-IIwithalessereffectonitsFCR.Asaconsequence,
we found a net decrease in apoA-II concentration with
weight loss. These effects of weight loss may be related to
its favourable impact on visceral ATM, insulin sensitivity
and plasma triacylglycerol concentrations.
Previous kinetic studies have only examined the
effects of changing the type or content of fat on HDL-
apoA-II transport kinetics [23–25]. V´ elez-Carrasco et al.
[23] reported that the consumption of low saturated
fat and cholesterol (Step 2 diet) had no effect on
HDL-apoA-II FCR or secretion rate. Brinton et al.
[24] found that subjects on a low-fat diet increased
HDL-apoA-II FCR without altering apoA-II levels or
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its secretion rate. Desroches et al. [25] observed that
a low-fat/high-carbohydrate diet decreased apoA-II
concentration with no effect on HDL-apoA-II kinetics.
However, most of these kinetic studies were of small
sample size, achieved minimal weight loss and did not
employ a weight control group nor a weight stabilization
period at the end of the study. In addition, these studies
were not restricted to obese subjects with dyslipidaemia.
In a placebo-controlled study with the use of stable
isotopes, we have examined previously the effects of
weight loss on apoB and apoA-I kinetics in subjects
with the MetS [19]. We have now extended the study by
investigating its impact on HDL-apoA-II metabolism.
It is likely that the combination of central obesity,
insulin resistance and hypertriacylglycerolaemia collect-
ively account for the dysregulation of HDL metabolism.
Therefore weight loss with a low-fat diet could correct
the abnormalities in HDL metabolism potentially by
improvements in insulin sensitivity and a reduction in
body weight. Consistent with this, we found that the
decrease in plasma apoA-II concentration was associated
with a reduction in plasma triacylglycerol, body weight
and, to a lesser extent, HOMA-IR.
HDL-apoA-II FCR
We have demonstrated previously that weight loss by a
low-fatlow-caloricdietlowersplasmatriacylglycerolsby
a reduction in VLDL production [18,19]. As described
earlier, this in turn decreases the VLDL-triacylglycerol
pool and subsequent CETP-mediated hetero-exchange
of neutral lipids among lipoproteins, thereby delaying
the uptake of HDL by the liver. This notion is consistent
with our present ﬁndings that weight loss decreased
HDL-apoA-II FCR; however, we found no signiﬁcant
correlation between the changes in HDL-apoA-II FCR
and plasma triacylglycerols. Given that apoA-I and
apoA-II are attached to HDL particles, one would anti-
cipate that the FCRs of HDL-apoA-I and -apoA-II
are tightly correlated. We did not ﬁnd a signiﬁcant
associationbetweenthechangesinFCRsofHDL-apoA-
I and -apoA-II with weight loss nor between the changes
in apoA-II FCR and HDL-cholesterol concentrations.
Taken together, it is likely that different mechanisms
underlie these alterations in HDL catabolism following
weight loss. That there was a signiﬁcant correlation
between the changes in HDL-apoA-II FCR and visceral
ATM indicates a potential role for adiposity in the regu-
lation of HDL-apoA-II catabolism. Whether the change
in HDL-apoA-II FCR was driven by the corresponding
changes in various adipocytokines merits investigation.
HDL-apoA-II production rate
The mechanism responsible for the decreased production
of HDL-apoA-II with weight loss in the MetS remains
unclear. Given the tight correlation between changes in
catabolism and production of HDL-apoA-II following
weight loss, it is possible that a ‘balancing feedback’
mechanism, as we observed in other interventional
kinetic studies [26,27], could account for the reduction
in apoA-II production rate. In contrast with apoA-II
FCR, we found that the decrease in the production
rate of HDL-apoA-II accounted for the reduction in
plasma apoA-II concentration. A change in apoA-II
production rate following weight loss was also associated
with reductions in plasma triacylglycerol concentration,
body weight and insulin resistance. This observation
suggests that weight loss by dietary restriction could
have a direct inﬂuence on apoA-II production. Using
VLDL-apoB kinetic data from the same subjects [19], we
found that the off-treatment production rates of VLDL-
apoB and HDL-apoA-II were signiﬁcantly correlated
(r=0.498, P=0.027), and that the fall in VLDL-
apoB production with weight loss was signiﬁcantly
and positively correlated with the reduction in the
HDL-apoA-II production rate (r= 0.506, P=0.023).
Moreover, in our previous cross-sectional studies [28],
we also observed signiﬁcant associations between the
production rates of VLDL-apoB, VLDL-apoC-III and
HDL-apoA-I. Taken together, it is likely that the global
effects of insulin resistance and/or obesity drive the
secretion of these lipoproteins and these are reversed by
weight loss. This notion is consistent with our present
ﬁndings.
Limitations
There are limitations to our present study. We acknow-
ledge that the effects of weight loss on apoA-II
kinetics cannot be fully dissociated from dietary effect,
in particular, changes in fat and carbohydrate intake.
However, we found no signiﬁcant associations between
changes in nutrient intake and changes in apoA-II
concentration and kinetics. In addition, our kinetic
studies were carried out during a weight stable period
and on an isocaloric diet. The alcohol intake in our
men was relatively high and the ﬁndings with apoA-II
kinetics may not necessarily translate to those with lesser
intake of alcohol intake. We only examined the short-
termeffectofweightlossfollowedbya2-weekisocaloric
weight-stabilizing period, but we have shown favourable
effects on lipoprotein metabolism with this regimen.
More prolonged periods of weight maintenance can lead
to rebound changes in plasma lipids that could mask the
full beneﬁt of weight loss. HDL particles are subjected to
modiﬁcationsbyseverallipaseandlipidtransferproteins,
particularly, LPL, HL, CETP and PLTP (phospholipid
transfer protein). We have reported previously that
weight loss had no effect on CETP and PLTP activity
[19]. Additional measurements of LPL and HL activities
in plasma may help to formally corroborate our ﬁndings.
OnlyobeseCaucasianmenwerestudied,anditispossible
that the kinetic effects of weight loss might have been
different in women and other ethnic groups.
C   The Authors Journal compilation C   2010 Biochemical Society
© 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.84 T. W. K. Ng and others
Implications
Recent evidence suggests that the cardioprotective effect
of the HDL system may relate chieﬂy to both the apoA-I
andapoA-IIcontentofHDLparticles.HigherapoA-Ire-
mains an independent negative predictor of cardiovascu-
lar risk [5]. An analysis from Epic-Norfolk showed that,
in apparently healthy people, increased plasma apoA-
II levels were predictive of lower coronary risk [9].
This challenges the previous notion that apoA-II is pro-
atherogenic [7,8]. Whether or not the apoA-II-lowering
effect with weight loss is anti-atherogeneic remains to be
elucidated and must also be viewed in light of the alter-
ations in apoB and apoA-I metabolic pathways. Import-
antly, how these effects impact upon the other functions
of HDL, including cholesterol efﬂux and whole-body
cholesterol turnover, merits further investigation.
In conclusion, we demonstrate that, in men with
the MetS, short-term weight loss with a low-fat diet
lowers the plasma apoA-II concentration by decreasing
both the production and catabolism of HDL-apoA-II.
Further investigations should explore the incremental
effect of other pharmacotherapies (e.g. ﬁbrates, ﬁsh oils
or insulin sensitizers) added to a weight loss regimen on
the functionality of HDL in these subjects.
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